Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Depreciation & Amortization (CF) (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $4.0 million as the latest value for Q1 2026.

  • For Q1 2026, Depreciation & Amortization (CF) changed N/A year-over-year to $4.0 million; the TTM value through Mar 2026 reached $4.0 million, changed N/A, while the annual FY2025 figure was $6.0 million, 25.0% down from the prior year.
  • Depreciation & Amortization (CF) hit $4.0 million in Q1 2026 for Syndax Pharmaceuticals, up from -$176000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $4.0 million in Q1 2026 and bottomed at $4.0 million in Q1 2026.